Phase 3 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, at a stage where surgery is considered possible, confirmed by a tissue or cell sample test
• People who are able to swallow and take anlotinib capsules by mouth
• People who have not previously received any systemic (whole-body) cancer treatment
• People with a good general performance level, able to carry out daily activities with little or no limitation (as rated by a standard medical scale called ECOG PS 0–1)
• People whose blood counts and organ function (including liver and kidneys) meet the specific healthy ranges required by the trial
• People who do not have serious ongoing complications or other major illnesses that cannot be managed
• People whose surgeon has assessed them as able to safely undergo the planned operation
• People of childbearing potential (both female and male with a partner who could become pregnant) who are willing to use a medically approved form of contraception during the study and for at least 6 months after the last chemotherapy dose
• People who have voluntarily agreed to take part, signed a consent form, and are willing to follow the study schedule and attend follow-up visits

Who may not be able to join:

• People with a body mass index (BMI) below 18.5 kg/m², or who have lost more than 10% of their body weight in the 2 months before screening
• People whose cancer has grown into the windpipe, major airways, or large blood vessels, or who have a deep ulcer in the oesophagus, a hole or abnormal connection in the digestive tract, significant bleeding, poor lung function, or a chronic lung condition diagnosed within the 6 months before starting treatment
• People who have severe difficulty swallowing and are unable to take oral anlotinib capsules
• People with a known allergy to any ingredient in the study medications, including the immunotherapy drug (anti-PD-1), albumin-bound paclitaxel, carboplatin, or similar platinum-based drugs
• People who have previously taken an experimental drug, are currently enrolled in another interventional clinical trial, or have previously received anti-cancer treatment or a live vaccine
• People with a history of active or ongoing autoimmune disease (conditions where the immune system attacks the body's own tissues)
• People with a history of immune system deficiency, a positive HIV test, other inherited or acquired immune disorders, or a history of organ transplant or bone marrow transplant from a donor
• People with heart or blood vessel conditions that are not well controlled
• People with active hepatitis B, hepatitis C, or active tuberculosis
• People who had a serious infection (such as severe pneumonia or a bloodstream infection requiring hospitalisation) within 4 weeks before starting the study, or signs of active lung inflammation or infection within 2 weeks before starting (unless taking antibiotics only as a precaution)
• People who have had major surgery (other than for diagnosis) within 28 days before treatment, or who are expected to need major surgery during the study
• People who have been diagnosed with another cancer within the past 5 years, with the exception of certain low-risk skin cancers or cervical conditions that have been fully treated and have a very high survival rate
• Women who are pregnant or breastfeeding, or who are unwilling or unable to use contraception
• People who, in the opinion of the trial investigator, have any other circumstances that may make it necessary for them to leave the study early

Important: Always verify eligibility with the trial site directly before applying.